GlassScriptPhysician profile
Amy Laurel Cable
NPI 1952879744
$4,203.66
in general payments reported to CMS, 2019-2025
27 companies · $812 in 2025
The $812 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $983 · 2023: $592 · 2024: $995 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,265.90 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $673.63 | 2021-2025 | |
| Lilly USA, LLC | $371.61 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $339.63 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $197.91 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $192.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $183.04 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.45 | 2021-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $124.23 | 2025 | Fanapt |
| Medtronic, INC. | $88.71 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $81.14 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.86 | 2024-2025 | Caplyta |
| Eisai INC. | $57.19 | 2025 | |
| Phathom Pharmaceuticals, INC. | $48.25 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $45.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $40.26 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.02 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $31.42 | 2025 | Ajovy |
| Gilead Sciences, INC. | $23.63 | 2023 | Epclusa |
| Seqirus USA INC | $19.96 | 2025 | Fluad, Flucelvax |
| Dexcom, INC. | $17.54 | 2021 | |
| Boston Scientific Corporation | $16.44 | 2022 | |
| Philips North America LLC | $15.16 | 2021 | |
| Astellas Pharma US INC | $12.83 | 2021 | |
| Mylan Specialty L.P. | $12.54 | 2022 | |
| Organon LLC | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.